GlassScriptPhysician profile
John L Couvaras
NPI 1790879799
$2,896.82
in general payments reported to CMS, 2019-2025
11 companies · $687 in 2025
The $687 reported for 2025 was more than what 90% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2021: $68.56 · 2022: $615 · 2023: $793 · 2024: $486 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $1,440.13 | 2021-2025 | Stripper, Origio Sequential Fert, Fisherbrand Disposable Liquid Infant Heel Warmer |
| Hologic Sales and Service, LLC | $237.47 | 2022-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Fluent Fluid Management System |
| Ferring Pharmaceuticals INC. | $207.65 | 2019-2025 | Menopur |
| Vitrolife INC. | $187.54 | 2023 | |
| Organon LLC | $153.71 | 2021-2025 | Follistim Aq, Ganirelix Acetate, Pregnyl |
| Becton, Dickinson and Company | $129.83 | 2025 | Bd Onclarity |
| Emd Serono, INC. | $123.97 | 2025 | |
| Abbvie INC. | $106.39 | 2019 | |
| Alexion Pharmaceuticals, INC. | $106.32 | 2019 | |
| Viiv Healthcare Company | $105.44 | 2023 | Apretude |
| Ascensia Diabetes Care US INC. | $98.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Couvaras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.